Double melanoma win for GSK: FDA OK's Mekinist, Tafinlar

What GlaxoSmithKline thought was going to be delayed until September came early for the London pharma, with the FDA on 29 May not only approving Mekinist (trametinib) ahead of schedule but also granting a nod to Tafinlar (dabrafenib) – both drugs winning the agency's OK as treatments for metastatic or unresectable melanoma.